Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Johnny N Mahlangu"'
Autor:
Aishatu Muhammad Nalado, Johnny N Mahlangu, Raquel Duarte, Graham Paget, Gbenga Olorunfemi, Barry F Jacobson, Saraladevi Naicker
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204899 (2018)
INTRODUCTION:Iron deficiency anaemia (IDA) worsens the prognosis and outcomes of chronic kidney disease (CKD). However, while the haemoglobin level is unreliable for early detection of IDA, reticulocyte haemoglobin content (CHr) and hypochromic red c
Externí odkaz:
https://doaj.org/article/b43d3f3043de48c097b82f89f7b0f99e
Autor:
Johnny N. Mahlangu
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors.
Externí odkaz:
https://doaj.org/article/09a4d49843014d85b91c59378740254d
Autor:
Johnny N. Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R. Malan, Silva Zupančić Šalek, Michael Wang, Lisa N. Boggio, Inga Hegemann, Andrzej Mital, Matthew Cardinal, Tong Zhu, Pengling Sun, Steven Arkin
Publikováno v:
British Journal of Haematology. 200:229-239
A phase 1b/2, three-month study of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), was conducted in participants with haemophilia A or B, with or without inhibitors. Participants assigned to four cohorts rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb8c475388ed35fd1098f9ae962f48c0
https://doi.org/10.1111/bjh.18420
https://doi.org/10.1111/bjh.18420
Autor:
Amy D. Shapiro, Roshni Daniel Kulkarni, Margaret V Ragni, Herve Chambost, Johnny N Mahlangu, Johannes Oldenburg, Beatrice Nolan, Margareth C Ozelo, Meredith C Foster, Annemieke Willemze, Chris Barnowski, Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, K John Pasi
Publikováno v:
Blood Advances.
Long-term efficacy and safety of the extended half-life recombinant FIX Fc fusion protein (rFIXFc) has been established in previously treated patients with severe hemophilia B in 2 Phase 3 trials (B-LONG [NCT01027364] and Kids B-LONG [NCT01440946]) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b3492f3b3a5f76dd4bbf7bdc817f3eb
https://doi.org/10.1182/bloodadvances.2022009230
https://doi.org/10.1182/bloodadvances.2022009230
Autor:
Pratima Chowdary, Margareta Holmström, Johnny N. Mahlangu, Margaret C. Ozelo, Ingrid Pabinger, K. John Pasi, Margaret V. Ragni, Amy Shapiro, Chris Barnowski, Stefan Lethagen
Publikováno v:
Research and Practice in Thrombosis and Haemostasis. 6:e12760
Background Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. Methods This analysis evaluates the efficacy and safety of extended half-life factor replacement recomb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1dbc299e18ee716a32cfbf794b52b0
https://doi.org/10.1002/rth2.12760
https://doi.org/10.1002/rth2.12760
Publikováno v:
Clinical Laboratory. 65
Background Von Willebrand disease requires laboratory confirmation with quantitative and qualitative measurements of von Willebrand factor (VWF). Qualitative VWF-activity (VWF-Ac) tests have poor inter- and intra-laboratory reproducibility with coeff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5729a652bd31909183d13ee033d8eaf8
https://doi.org/10.7754/clin.lab.2018.180919
https://doi.org/10.7754/clin.lab.2018.180919
Autor:
Aishatu Muhammad, Nalado, Caroline, Dickens, Therese, Dix-Peek, Johnny N, Mahlangu, Gbenga, Olorunfemi, Graham, Paget, Raquel, Duarte, Saraladevi, Naicker
Publikováno v:
International journal of molecular epidemiology and genetics. 10(1)
Background: In genome-wide studies, there is a strong association between the TMPRSS6 allele A736V (rs855791) and significantly lower levels of serum iron, transferrin saturation, haemoglobin, and mean corpuscular volumes. The influence of this genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f8eb11d3cfcac9e3c4419e375f8ab5e6
https://pubmed.ncbi.nlm.nih.gov/30911357
https://pubmed.ncbi.nlm.nih.gov/30911357
Autor:
Johnny N. Mahlangu, Pei Lin Koh, Heng Joo Ng, Toshko Lissitchkov, Marion Hardtke, Jens Schroeder
Publikováno v:
Blood. 122:573-573
Introduction Up to 30% of patients with hemophilia A and 5% of patients with hemophilia B develop neutralizing antibodies (inhibitors) against replacement factor VIII or factor IX, respectively. Acute bleeding episodes in these patients with inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f114e812f2c846d43d196ad0af115d6c
https://doi.org/10.1182/blood.v122.21.573.573
https://doi.org/10.1182/blood.v122.21.573.573